Evaluation of the Utility of Baseline Echocardiogram in Patients With Standard Risk Precursor B‐Lymphoblastic Leukemia
Pediatric Blood & Cancer · 2026-06 · 73 (6)
DOI: 10.1002/1545-5017.70265 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 19.03.2026. Verfasst von Ziyad Alrajhi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Echocardiography, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Anthracyclines. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
A routine baseline echocardiogram is often obtained prior to anthracycline administration in children with cancer. The utility of baseline echocardiogram is unclear in patients with standard risk B‐cell acute lymphoblastic leukemia (SR B‐ALL) as their anthracycline cumulative dose is low. We performed a quality improvement project to understand the clinical utility of routine pre‐anthracycline echocardiograms in patients with SR B‐ALL.
Methods
We retrospectively reviewed baseline echocardiogram results for all children with SR B‐ALL treated at a single center from 2011 to 2024. Echocardiographic findings, including any significant structural or functional abnormalities, and the impact of echocardiogram results on anthracycline administration were analyzed.
Results
A total of 286 patients with a median age at diagnosis of 4.13 years [IQR 2.92–5.52] were included. Abnormal echocardiographic findings were reported in six patients (2.1%), but mainly represented incidental findings with only one patient requiring cardiology follow‐up for a bicuspid aortic valve. No echocardiogram identified reduced cardiac function or any finding that altered or delayed anthracycline administration.
Conclusion
A routine baseline echocardiogram in patients with SR B‐ALL prior to anthracycline administration is without clear utility. Based on these results, a change in practice was implemented in our institution to discontinue routine pre‐anthracycline echocardiograms for this population. Omitting this low‐value test may reduce unnecessary discomfort in children, family worry, and health‐care‐related costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
- Department of Pediatric Hematology and Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
- Division of Cardiology, The Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Paediatric Cardiology Unit, Department of Women's and Children's Health, University of Padua, Padua, Italy.
ORCID-Profile: Adam Paul Yan
Zitieren
APA
Alrajhi, Z., Pozza, A., Mertens, L., Yan, A. P., & Alexander, S. (2026). Evaluation of the Utility of Baseline Echocardiogram in Patients With Standard Risk Precursor B‐Lymphoblastic Leukemia. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70265
Vancouver
Alrajhi Z, Pozza A, Mertens L, Yan AP, Alexander S. Evaluation of the Utility of Baseline Echocardiogram in Patients With Standard Risk Precursor B‐Lymphoblastic Leukemia. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70265
BibTeX
@article{Alrajhi2026,
author = {Alrajhi, Ziyad and Pozza, Alice and Mertens, Luc and Yan, Adam Paul and Alexander, Sarah},
title = {Evaluation of the Utility of Baseline Echocardiogram in Patients With Standard Risk Precursor B‐Lymphoblastic Leukemia},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {6},
doi = {10.1002/1545-5017.70265}
}
EUVIMED